ArticleHealth science reports2025
Evaluation of Inhaled Colistin/Fosfomycin as an Adjunctive Treatment for Ventilator-Associated Pneumonia: A Preliminary Study.
Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Fosfomycin as an adjunctive agent against carbapenem-resistant Acinetobacter baumannii: an updated narrative review.Infection · 2026Review
- Evaluation of Inhaled Colistin/Fosfomycin as an Adjunctive Treatment for Ventilator-Associated Pneumonia: A Preliminary Study.Health science reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Ventilator-associated pneumonia (VAP) caused by gram-negative bacteria is associated with significant complications, mortality, and resource utilization. Over the past decade, there has been growing interest in using fosfomycin to treat multidrug-resistant gram-negative infections, particularly when limited viable options remain. This study aimed to investigate the efficacy of inhaled colistin/fosfomycin as an adjunctive treatment for VAP. Methods: In this triple-blind clinical trial, participants with VAP caused by extensively drug-resistant (XDR) Results: While the differences were not statistically significant ( Conclusion: The study demonstrated that the addition of inhaled colistin/fosfomycin to the treatment regimen may result in faster recovery and shorter treatment duration for patients with VAP caused by XDR
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.